• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Elevai Labs, Inc. - Common Stock (NQ: ELAB )

    0.3200 +0.0536 (+20.12%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 47,042,202
    Open 0.3000
    Bid (Size) 0.2800 (36)
    Ask (Size) 0.2919 (2)
    Prev. Close 0.2664
    Today's Range 0.2771 - 0.3760
    52wk Range 0.2175 - 4.244
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology
    From Elevai Labs Inc.
    Via GlobeNewswire
    12 Consumer Staples Stocks Moving In Monday's After-Market Session
    Via Benzinga

    Performance

    YTD
    -83.07%
    -83.07%
    1 Month
    -4.22%
    -4.22%
    3 Month
    -51.88%
    -51.88%
    6 Month
    -56.17%
    -56.17%
    1 Year
    -90.59%
    -90.59%

    More News

    Read More
    Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™
    From Elevai Labs Inc.
    Via GlobeNewswire
    ELAB Stock Earnings: Elevai Labs Reported Results for Q2 2024
    Via InvestorPlace
    ELAB Stock Earnings: Elevai Labs Reported Results for Q1 2024
    Via InvestorPlace
    Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum
    From Elevai Labs Inc.
    Via GlobeNewswire
    Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why Workday Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications
    From Elevai Labs Inc.
    Via GlobeNewswire
    Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Elevai Labs Inc.
    Via GlobeNewswire
    Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD
    From Elevai Labs Inc.
    Via GlobeNewswire
    Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Top 4 Risk Off Stocks You'll Regret Missing In July
    Via Benzinga
    Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line
    From Elevai Labs Inc.
    Via GlobeNewswire
    Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024
    From Elevai Labs Inc.
    Via GlobeNewswire
    Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
    From Elevai Labs Inc.
    Via GlobeNewswire
    Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm
    From Elevai Labs Inc.
    Via GlobeNewswire
    Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
    From Elevai Labs Inc.
    Via GlobeNewswire
    Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
    Via News Direct
    Elevai Labs Inc. Reports First Quarter 2024 Financial Results
    From Elevai Labs Inc.
    Via GlobeNewswire
    Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
    From Elevai Labs Inc.
    Via GlobeNewswire
    12 Consumer Staples Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
    From Elevai Labs Inc.
    Via GlobeNewswire
    Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
    From Elevai Labs Inc.
    Via GlobeNewswire
    Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
    From Elevai Labs Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.